Stock listing

NASDAQ:STOK Stoke Therapeutics, Inc. Stock

Home listing (NASDAQ) of Stoke Therapeutics, Inc.

Follow Stoke Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:STOK

$24.82 USD +0.65 (+2.7%)

Close on Oct 19, 2026

Since Jul 6, 2026 -23.5% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$24.13 – $25.02 USDOct 19, 2026
Volume
694,712 sharesOct 19, 2026
Market value
$1.60B USDAt the close on Oct 19, 2026 · price × 64.53M shares outstanding
Stoke Therapeutics, Inc. logo
Ticker
NASDAQ:STOK
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Stoke Therapeutics (NASDAQ:STOK) Q2 2026 Earnings Call

    Mon, Aug 03, 2026 · 4:30 PM ET

    Watch Transcript

  • Stoke Therapeutics (NASDAQ:STOK) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 4:30 PM ET

    Watch Transcript

  • Stoke Therapeutics (NASDAQ:STOK) Q3 2025 Earnings Call

    Tue, Nov 04, 2025 · 4:30 PM ET

    Watch Transcript

Latest news

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Oct 16, 2026

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting

Oct 12, 2026

Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Oct 5, 2026

Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization

Sep 23, 2026

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

Sep 1, 2026

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Aug 5, 2026

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

Aug 3, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

Jul 27, 2026

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

Jul 13, 2026

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Jun 30, 2026

All Stoke Therapeutics, Inc. news

Decks

Stoke Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 147 in all · newest Oct 16, 2026 · oldest 2019
Calls
5 calls with a replay · 5 with a transcript · latest Aug 3, 2026
Decks
20 decks · latest Aug 3, 2026

Where Stoke Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:STOK · Home listing · This pageNASDAQUnited StatesUSD
gettex:0GTgettexGermanyEUR
Lang & Schwarz:A2PLTLLang & SchwarzGermanyEUR
LS Exchange:A2PLTLLS ExchangeGermanyEUR
BOATS:STOKBOATSUnited StatesUSD
Frankfurt:0GTFrankfurtGermanyEUR
Tradegate:0GTTradegateGermanyEUR
Dusseldorf:0GTDusseldorfGermanyEUR
Munich:0GTMunichGermanyEUR
Stuttgart:0GTStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Stoke Therapeutics, Inc.